A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks

Jacqueline N Poston; Jonathan R Fromm; Heather A Rasmussen; Andrei R Shustov; Edward N Libby 3rd; Stephen D Smith; Ted Gooley; Ajay K Gopal

doi:10.1111/bjh.15742

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks

Br J Haematol. 2019 Jul;186(1):159-162. doi: 10.1111/bjh.15742. Epub 2018 Dec 28.

Authors

Jacqueline N Poston^{1

2

3

4}, Jonathan R Fromm^{4

5}, Heather A Rasmussen¹, Andrei R Shustov^{2

3

4}, Edward N Libby 3rd^{1

2

4}, Stephen D Smith^{1

2

4}, Ted Gooley², Ajay K Gopal^{1

2

4}

Affiliations

¹ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
⁴ Seattle Cancer Care Alliance, Seattle, WA, USA.
⁵ Department of Laboratory Medicine, Division of Hematopathology, University of Washington, Seattle, WA, USA.

No abstract available

Keywords: CD30; Hodgkin lymphoma; anaplastic large cell lymphoma; brentuximab vedotin.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Brentuximab Vedotin / administration & dosage*
Drug Administration Schedule
Drug Resistance, Neoplasm*
Humans
Ki-1 Antigen
Lymphoma, Large-Cell, Anaplastic / drug therapy*
Pilot Projects

Substances

Antineoplastic Agents, Immunological
Ki-1 Antigen
Brentuximab Vedotin

Publication types

MeSH terms

Substances

Grants and funding